PMID- 22068611
OWN - NLM
STAT- MEDLINE
DCOM- 20120514
LR  - 20211203
IS  - 1420-9071 (Electronic)
IS  - 1420-682X (Linking)
VI  - 69
IP  - 8
DP  - 2012 Apr
TI  - The role of mammalian target of rapamycin (mTOR) in the regulation of pancreatic 
      beta-cell mass: implications in the development of type-2 diabetes.
PG  - 1289-304
LID - 10.1007/s00018-011-0874-4 [doi]
AB  - Type-2 diabetes mellitus (T2DM) is a disorder that is characterized by high blood 
      glucose concentration in the context of insulin resistance and/or relative 
      insulin deficiency. It causes metabolic changes that lead to the damage and 
      functional impairment of organs and tissues resulting in increased morbidity and 
      mortality. It is this form of diabetes whose prevalence is increasing at an 
      alarming rate due to the 'obesity epidemic', as obesity is a key risk factor in 
      the development of insulin resistance. However, the majority of individuals who 
      have insulin resistance do not develop diabetes due to a compensatory increase in 
      insulin secretion in response to an increase in insulin demand. This adaptive 
      response is sustained by an increase in both beta-cell function and mass. 
      Importantly, there is increasing evidence that the Serine/Threonine kinase 
      mammalian target of rapamycin (mTOR) plays a key role in the regulation of beta-cell 
      mass and therefore likely plays a critical role in beta-cell adaptation. Therefore, 
      the primary focus of this review is to summarize our current understanding of the 
      role of mTOR in stimulating pancreatic beta-cell mass and thus, in the prevention of 
      type-2 diabetes.
FAU - Xie, Jianling
AU  - Xie J
AD  - Department of Cell Physiology and Pharmacology, University of Leicester, UK.
FAU - Herbert, Terence P
AU  - Herbert TP
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20111109
PL  - Switzerland
TA  - Cell Mol Life Sci
JT  - Cellular and molecular life sciences : CMLS
JID - 9705402
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Type 2/genetics/*metabolism
MH  - Humans
MH  - Insulin-Secreting Cells/*metabolism
MH  - Obesity/metabolism
MH  - TOR Serine-Threonine Kinases/genetics/*metabolism
EDAT- 2011/11/10 06:00
MHDA- 2012/05/15 06:00
CRDT- 2011/11/10 06:00
PHST- 2011/09/05 00:00 [received]
PHST- 2011/10/20 00:00 [accepted]
PHST- 2011/10/20 00:00 [revised]
PHST- 2011/11/10 06:00 [entrez]
PHST- 2011/11/10 06:00 [pubmed]
PHST- 2012/05/15 06:00 [medline]
AID - 10.1007/s00018-011-0874-4 [doi]
PST - ppublish
SO  - Cell Mol Life Sci. 2012 Apr;69(8):1289-304. doi: 10.1007/s00018-011-0874-4. Epub 
      2011 Nov 9.